Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
April 26 2023 - 7:00AM
Business Wire
Company-Sponsored Educational Events will
Focus on Dry Eye Disease and IC-8® Apthera™ Intraocular
Lens
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a
leading global eye health company dedicated to helping people see
better to live better, today announced the presentation of 21
podium presentations and four poster presentations related to the
company’s products and pipeline programs during the American
Society of Cataract and Refractive Surgery (ASCRS) annual meeting,
which will take place in San Diego from May 5-8, 2023.
The posters and presentations include two studies assessing the
new StableVisc™ cohesive ophthalmic viscosurgical device, which
Bausch + Lomb commercially launched this month. Others include a
retrospective chart review on the use of LOTEMAX® SM (loteprednol
etabonate ophthalmic gel) 0.38% in refractive surgery and numerous
presentations focused on Bausch + Lomb surgical IOL pipeline
programs. New data from the Bausch + Lomb Antibiotic Resistance
Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will
also be presented.
Bausch + Lomb will also sponsor two educational events during
the meeting. One will address dry eye disease (DED), one of the
most common ocular surface disorders.1 Approximately 18 million
Americans have diagnosed DED.2 The second will discuss the IC-8
Apthera lens.
The complete list of scientific podium and e-poster
presentations, as well as details for the featured education events
is as follows:
Podium Presentations
- “Aberration-free Monofocal Hydrophobic Toric IOL Targeted for
Emmetropia or Mini-Monovision: Assessment of Visual and Refractive
Outcomes.” Epitropoulus et al.
- “A Novel Small Aperture IOL Provides a More Continuous Range of
Vision When Compared to Traditional Monovision.” Yeu et al.
- “Comparison of Clinical Results in Post-Refractive and
Non-Refractive Patients Implanted with Aberration Free Monofocal
IOL.” Hu et al.
- “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal
IOLs Implanted Bilaterally in Cataract Patients.” Shultz et
al.
- “Clinical Outcome of Conventional PRK vs. New Transepi PRK.”
Ang et al.
- “Clinical Outcomes and Patient Satisfaction of a New Enhanced
Depth of Focus IOL.” Artashes A. Zilfyan et al.
- “Evaluating the Performance of Small Aperture Optics on
Irregular Astigmatism.” Koch et al.
- “Evaluating Vision after Contralateral Implantation of Small
Aperture IOL with Low Amounts of Corneal Astigmatism.” Hovanesian
et al.
- “Evaluation of Patient-Reported Outcomes Following Bilateral
Implantation of Two Preloaded Monofocal IOLs.” Shultz et al.
- “Ex Vivo Comparative User Evaluation of a New Cohesive
Ophthalmic Viscosurgical Device (OVD).” Stephenson et al.
- “IC-8 for Complex Corneas, Session 3 New Technologies,
Refractive Day.” Ang et al.
- “IC-8 for Low Astigmatism, Refractive Cataract Surgery to the
Max.” Hovanesian et al.
- “Importance of Total Corneal Astigmatism When Planning Toric
IOLs for Astigmatism Correction.” Stephenson et al.
- “Long Term Visual and PRO Outcomes of Small Aperature IOL in
Post Refractive Eyes.” Ang et al.
- “Outcomes of Rasch-Scaled CatQuest-9SF Questionnaire Before and
After Implantation of Aberration-Free, Hydrophobic Toric IOL.”
Liang et al.
- “Rotational Stability of an Aberration-Free Hydrophobic Toric
IOL with a Broad Haptic-Capsular Bag Contact Angle.” Wiley et
al.
- “Safety and Effectiveness Comparison of a New Cohesive
Ophthalmic Viscosurgical Device (OVD).” Shultz et al.
- “Safety and Performance of a New One-Piece Hydrophobic Acrylic
Trifocal Intraocular Lens.” Harasymowycz et al.
- “Small Aperture IOL Provides High Quality Continuous Range of
Vision.” Thompson et al.
- “The Analysis of the Refractive and Visual Outcomes for the
Novel Excimer Laser Ablation Algorithm in Myopic Eyes.” Artashes A.
Zilfyan et al.
- “Visual Performance of a Low Cylinder Powered (0.9D) Toric
Intraocular Lens Compared to Non-Toric Intraocular Lens.” Muzychuk
et al.
E-Poster Presentations
- “Astigmatic Outcomes Following Implantation of High-Powered
Toric (≥2.75 D) Hydrophobic Acrylic IOL with Aberration-Free
Optics.” Sadri et al.
- “Clinical Outcomes Following Implantation of an Aberration-Free
Hydrophobic Toric IOL Across the Range of Toricities (1.25 D to
5.75 D).” Sadri et al.
- “In Vitro Antibiotic Resistance of Intraocular Bacterial
Pathogens from the ARMOR Surveillance Study.” Asbell et al.
- “Retrospective Chart Review on the Use of LOTEMAX® SM in
Refractive Surgery.” Salinger et al.
Featured Education Events Saturday,
May 6
- "Modernizing Monovision with IC-8® Apthera™" 3:00-4:00 p.m. PT
at the ASCRS Tap Room (booth #1511) in the San Diego Convention
Center Vance Thompson, M.D., will lead an informative presentation
on the IC-8 Apthera small aperture IOL.
- "All Eyes on Evaporation" 7:15-8:15 p.m. PT at Roy’s Restaurant
in the Marriott Marquis San Diego Marina Kendall Donaldson, M.D.,
and Marjan Farid, M.D., will discuss current thinking on the role
of evaporation in DED, reviewing causative factors, DED
pathophysiology, diagnostic approaches and current treatments.
Register in advance:
https://na.eventscloud.com/website/54369/.
Important Safety Information about LOTEMAX® SM (loteprednol
etabonate ophthalmic gel) 0.38%
INDICATION LOTEMAX® SM (loteprednol etabonate ophthalmic
gel) 0.38% is a corticosteroid indicated for the treatment of
post-operative inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
- LOTEMAX® SM, as with other ophthalmic corticosteroids, is
contraindicated in most viral diseases of the cornea and
conjunctiva including epithelial herpes simplex keratitis
(dendritic keratitis), vaccinia, and varicella, and also in
mycobacterial infection of the eye and fungal diseases of ocular
structures.
- Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields of
vision. Steroids should be used with caution in the presence of
glaucoma. If LOTEMAX® SM is used for 10 days or longer, IOP should
be monitored.
- Use of corticosteroids may result in posterior subcapsular
cataract formation.
- The use of steroids after cataract surgery may delay healing
and increase the incidence of bleb formation. In those with
diseases causing thinning of the cornea or sclera, perforations
have been known to occur with the use of topical steroids. The
initial prescription and renewal of the medication order should be
made by a physician only after examination of the patient with the
aid of magnification such as slit lamp biomicroscopy and, where
appropriate, fluorescein staining.
- Prolonged use of corticosteroids may suppress the host response
and thus increase the hazard of secondary ocular infections. In
acute purulent conditions, steroids may mask infection or enhance
existing infections.
- Employment of a corticosteroid medication in the treatment of
patients with a history of herpes simplex requires great caution.
Use of ocular steroids may prolong the course and may exacerbate
the severity of many viral infections of the eye (including herpes
simplex).
- Fungal infections of the cornea are particularly prone to
develop coincidentally with long-term local steroid application.
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
cultures should be taken when appropriate.
- Contact lenses should not be worn when the eyes are
inflamed.
- There were no treatment-emergent adverse drug reactions that
occurred in more than 1% of subjects in the three times daily group
compared to vehicle.
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
Click here for full Prescribing Information for LOTEMAX®
SM.
About Bausch + Lomb Bausch + Lomb is dedicated to
protecting and enhancing the gift of sight for millions of people
around the world – from the moment of birth through every phase of
life. Its comprehensive portfolio of more than 400 products
includes contact lenses, lens care products, eye care products,
ophthalmic pharmaceuticals, over-the-counter products and
ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb has a significant global research and development,
manufacturing and commercial footprint with approximately 13,000
employees and a presence in nearly 100 countries. Bausch + Lomb is
headquartered in Vaughan, Ontario with corporate offices in
Bridgewater, New Jersey. For more information, visit www.bausch.com
and connect with us on Twitter, LinkedIn, Facebook and
Instagram.
Forward-looking Statements This news release may contain
forward-looking statements, which may generally be identified by
the use of the words “anticipates,” “hopes,” “expects,” “intends,”
“plans,” “should,” “could,” “would,” “may,” “believes,”
“estimates,” “potential,” “target,” or “continue” and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch + Lomb’s filings with
the U.S. Securities and Exchange Commission and the Canadian
Securities Administrators, which factors are incorporated herein by
reference. They also include, but are not limited to, risks and
uncertainties caused by or relating to the evolving COVID-19
pandemic, and the fear of that pandemic and its potential effects,
the severity, duration and future impact of which are highly
uncertain and cannot be predicted, and which may have a material
adverse impact on Bausch + Lomb, including but not limited to its
project development timelines, launches and costs (which may
increase). Readers are cautioned not to place undue reliance on any
of these forward-looking statements. These forward-looking
statements speak only as of the date hereof. Bausch + Lomb
undertakes no obligation to update any of these forward-looking
statements to reflect events or circumstances after the date of
this news release or to reflect actual outcomes, unless required by
law.
References
- Leonardi, A., Modugno, R. L., & Salami, E. (2021). Allergy
and Dry Eye Disease. Ocular immunology and inflammation, 29(6),
1168–1176. https://doi.org/10.1080/09273948.2020.1841804.
- 2020 Dry Eye Products Market Report: A global Analysis for 2019
to 2025. Market Scope. Retrieved from
https://www.market-scope.com/pages/reports/250/2020-ophthalmic-landscape-report-global-analysis-for-2019-to-2025-april-2021#reports.
© 2023 Bausch + Lomb. MTB.0117.USA.23
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230426005117/en/
Investors: Arthur Shannon arthur.shannon@bausch.com
Allison Ryan allison.ryan@bausch.com (877) 354-3705 (toll free)
(908) 927-0735
Media: Lainie Keller lainie.keller@bausch.com (908)
927-1198
Kristy Marks kristy.marks@bausch.com (908) 927-0683
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bausch plus Lomb (NYSE:BLCO)
Historical Stock Chart
From Jul 2023 to Jul 2024